SCHEMBL790635

SCHEMBL790635

SCCNc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.64
MAPT P10636 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.54
HDAC3 O15379 8/20 0.48
HDAC4 P56524 8/20 0.48
HDAC1 Q13547 8/20 0.48
HDAC7 Q8WUI4 8/20 0.48
HDAC2 Q92769 8/20 0.48
HDAC10 Q969S8 8/20 0.48
HDAC11 Q96DB2 8/20 0.48
HDAC8 Q9BY41 8/20 0.48
HDAC6 Q9UBN7 8/20 0.48
HDAC9 Q9UKV0 8/20 0.48
HDAC5 Q9UQL6 8/20 0.48
IDO1 P14902 1/20 0.43
DPP7 Q9UHL4 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
CTSD P07339 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159752 0.85 ALDH1A1 (0.73) ALDH1A1MAPTL3MBTL1HDAC3HDAC4
SCHEMBL4164952 0.83 ALDH1A1 (0.70) ALDH1A1MAPTL3MBTL1HDAC3HDAC4
SCHEMBL232188 0.83 MAPT (0.78) ALDH1A1MAPTL3MBTL1IDO1HRH3
SCHEMBL15902716 0.81 ALDH1A1 (0.67) ALDH1A1MAPTL3MBTL1HDAC3HDAC4
SCHEMBL6416019 0.80 MAPT (0.74) ALDH1A1MAPTL3MBTL1IDO1HRH3
SCHEMBL1562142 0.80 MAPT (0.74) ALDH1A1MAPTL3MBTL1IDO1HRH3
SCHEMBL1469563 0.78 MAPT (0.41) ALDH1A1MAPTL3MBTL1HDAC3HDAC4
SCHEMBL4970157 0.78 ALDH1A1 (0.89) ALDH1A1MAPTL3MBTL1HDAC3HDAC1
SCHEMBL820286 0.78
SCHEMBL2065279 0.78 ALDH1A1 (1.00) ALDH1A1MAPTL3MBTL1HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117599029-A Compositions for controlled release of cysteamine and systematic treatment of cysteamine-sensitive disorders 硫创治疗公司 2024-02-27 CN disclosed
US-20230161252-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-25 US disclosed
US-20230161252-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-25 US disclosed
US-20230161255-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-25 US disclosed
US-20230161255-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-25 US disclosed
EP-2968440-B1 CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME ZYMEWORKS INC (CA) 2019-06-05 EP disclosed
US-9889115-B2 Fitness assay and associated methods BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2018-02-13 US disclosed
US-9249181-B2 C-terminal amidation of polypeptides AMYLIN PHARMACEUTICALS, LLC (US) 2016-02-02 US disclosed
EP-1088098-B2 FITNESS ASSAY AND METHODS FOR REDUCING RESISTANCE OF HIV TO THERAPY US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) 2015-07-01 EP disclosed
US-20140058070-A1 C-TERMINAL AMIDATION OF POLYPEPTIDES AstraZeneca Pharmaceuticala LP (US) 2014-02-27 US disclosed
WO-1997033866-A1 β-ANILINOETHANETHIOL COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF, AND PROCESS FOR PREPARING 3,4-DIHYDRO-2H-1,4-BENZOTHIAZINE COMPOUNDS THEREFROM UBE INDUSTRIES, LTD. (JP) 1997-09-18 WO disclosed
EP-0303489-B1 Polyether-ester amide and permanently antistatic resin composition TORAY INDUSTRIES (JP) 1995-03-01 EP disclosed
US-5096995-A Copolymerization of aminocarboxylic acid or lactam and a diol compound; integrated circuit carrier cases TORAY INDUSTRIES, INC. (JP) 1992-03-17 US disclosed
EP-0304134-A2 Magnetic resin composition DSM N.V. (NL) 1989-02-22 EP disclosed
EP-0164987-A2 7-Oxabicycloheptane substituted prostaglandin analogs E.R. Squibb & Sons, Inc. (US) 1985-12-18 EP disclosed
US-4555523-A 7-Oxabicycloheptane substituted thio prostaglandin analogs and their use in the treatment of thrombolytic disease E. R. SQUIBB & SONS, INC. (US) 1985-11-26 US disclosed
EP-0159519-A2 Use of thio compounds for the prevention of hair fall-out caused by cytostatics Asta-Werke Aktiengesellschaft Chemische Fabrik (DE) 1985-10-30 EP disclosed
US-4012317-A Process for extracting urea from a solution with alkenylaromatic polymers with α-ketoalhydic groups RHONE-POULENC S.A. (FR) 1977-03-15 US disclosed
US-3954997-A MITICIDES, INSECTICIDES THE UPJOHN COMPANY (US) 1976-05-04 US disclosed
US-3933753-A Alkenylaromatic polymers with α-ketoalhydic groups RHONE-POULENC S.A. (FR) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140058070-A1 C-TERMINAL AMIDATION OF POLYPEPTIDES IAPP, SELENOI, SCLY ALDH1A1 4215/4885MAPT 3990/4885L3MBTL1 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.